Dendreon Reports Third Quarter 2007 Financi...( - Management Will Host Con...)

- Management Will Host Conference Call at 1:30 PM ET -

SEATTLE, Nov. 15 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the quarter ended September 30, 2007. Revenue for the third quarter of 2007 was $112,000 compared to $84,000 for the quarter ended September 30, 2006. Revenue for the nine months ended September 30, 2007 was $715,000 compared to $187,000 for the nine months ended September 30, 2006.

Dendreon's total operating expenses for the third quarter of 2007 were $19.8 million compared to $21.7 million in 2006. Dendreon's total operating expenses for the nine months ended September 30, 2007 were $75.2 million compared to $73.6 million for the same period in 2006.

The net loss for the quarter ended September 30, 2007 was $19.2 million, or $0.23 per share, compared to a net loss of $20.7 million, or $0.29 per share, for the quarter ended September 30, 2006. The net loss for the nine months ended September 30, 2007 was $72.3 million, or $0.88 per share, compared to $70.2 million, or $0.98 per share for the nine months ended September 30, 2006.

Cash, cash equivalents and short-term and long-term investments at September 30, 2007 totaled $138.8 million compared to $121.3 million at December 31, 2006.

Recent Highlights:

-- Completed enrollment of over 500 patients in the Phase 3 IMPACT

(IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as

D9902B) clinical trial of PROVENGE(R) (sipuleucel-T). Dendreon

received confirmation that the FDA will accept either a positive

interim or positive final analysis of overall survival from the IMPACT

study to amend the Biologics License App
'/>"/>